2Seventy Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TSVT Nasdaq 8731 https://www.2seventybio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for 2Seventy Bio Inc

2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia - May 19th, 2023 10:00 am
2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio - May 17th, 2023 11:17 am
2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023 - May 11th, 2023 4:37 pm
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress - May 3rd, 2023 8:05 pm
2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting - May 2nd, 2023 8:37 pm
Billionaire Ken Griffin Doubles Down on These 2 ‘Strong Buy’ Stocks ⁠— Here’s Why You Might Want to Follow in His Footsteps - May 2nd, 2023 2:00 pm
2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program - May 1st, 2023 11:00 am
2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023 - Apr 28th, 2023 12:30 pm
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma - Apr 17th, 2023 10:59 am
2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress - Mar 16th, 2023 8:05 pm
2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors - Mar 8th, 2023 1:30 pm
2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference - Mar 3rd, 2023 12:00 pm
Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer - Mar 1st, 2023 2:00 pm
2seventy bio Announces Pricing of Upsized Public Offering of Common Stock - Mar 1st, 2023 2:00 am
2seventy bio Announces Proposed Public Offering of Common Stock - Feb 28th, 2023 9:01 pm
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study - Feb 10th, 2023 4:13 pm
2seventy bio to Participate in Upcoming Investor Conferences - Feb 1st, 2023 12:30 pm
Medigene Receives $3 Million Milestone Payment from 2seventy bio - Jan 18th, 2023 4:35 pm
2seventy bio Provides Company Outlook for 2023 - Jan 9th, 2023 1:00 pm
2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors - Jan 6th, 2023 2:11 pm